Insulet Corporation (PODD)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Insulet Corporation (PODD)
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Key Insights
Critical company metrics and information
Share Price
$265.46Market Cap
$18.62 BillionTotal Outstanding Shares
70.15 Million SharesTotal Employees
3,000Dividend
No dividendIPO Date
May 15, 2007SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.insulet.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $-109.80 Million |
Net Cash Flow, Continuing | $213.00 Million |
Net Cash Flow From Operating Activities, Continuing | $327.80 Million |
Net Cash Flow From Investing Activities, Continuing | $-109.80 Million |
Net Cash Flow From Operating Activities | $327.80 Million |
Net Cash Flow From Financing Activities, Continuing | $-5.00 Million |
Net Cash Flow From Financing Activities | $-5.00 Million |
Net Cash Flow | $217.20 Million |
Exchange Gains/Losses | $4.20 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Attributable To Parent | $420.90 Million |
Operating Expenses | $1.07 Billion |
Revenues | $1.98 Billion |
Selling, General, and Administrative Expenses | $869.00 Million |
Gross Profit | $1.38 Billion |
Benefits Costs and Expenses | $1.69 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Operating Income/Loss | $306.00 Million |
Research and Development | $201.00 Million |
Income Tax Expense/Benefit | $-124.20 Million |
Net Income/Loss Available To Common Stockholders, Basic | $420.90 Million |
Income/Loss From Continuing Operations After Tax | $420.90 Million |
Costs And Expenses | $1.69 Billion |
Diluted Average Shares | $77.35 Million |
Basic Average Shares | $70.08 Million |
Net Income/Loss | $420.90 Million |
Basic Earnings Per Share | $6.01 |
Income/Loss From Continuing Operations Before Tax | $296.70 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Diluted Earnings Per Share | $5.87 |
Cost Of Revenue | $607.90 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Assets | $3.03 Billion |
Inventory | $444.90 Million |
Other Current Assets | $1.42 Billion |
Noncurrent Assets | $1.16 Billion |
Liabilities And Equity | $3.03 Billion |
Noncurrent Liabilities | $1.40 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Liabilities | $506.20 Million |
Other Current Liabilities | $465.90 Million |
Equity Attributable To Parent | $1.12 Billion |
Equity | $1.12 Billion |
Accounts Payable | $40.30 Million |
Liabilities | $1.91 Billion |
Current Assets | $1.86 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.